Loading clinical trials...
Loading clinical trials...
Phase 1/2 Open-Label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Conditions
Interventions
IMO-8400
Locations
10
United States
Cancer Centers of Excellence
Fayetteville, Arkansas, United States
UCLA
Los Angeles, California, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Emory Winship Cancer Institute
Atlanta, Georgia, United States
Horizon BioAdvance
Lafayette, Indiana, United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
March 1, 2014
Primary Completion Date
April 1, 2017
Completion Date
November 1, 2017
Last Updated
September 10, 2019
NCT04274738
NCT01647971
NCT01046006
NCT01125293
NCT00936611
NCT02363439
Lead Sponsor
Idera Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions